Autoplay Next video from Max length

FDA approves Phase II clinical trial of stem cells for Lou Gehrig's disease (ALS)

2,637 views · Published 17 April 2013 · 1:48 · Indexed 12 November 2026

Channel: Michigan Medicine · 2013 · Education

Dr. Eva Feldman, U-M neurologist and director of the A. Alfred Taubman Medical Research Institute, discusses the recent FDA approval of a new phase for a clinical trial of stem cell injections in patients with deadly Lou Gehrig's disease. The approval paves the way for the trial to open at U-M, pending approval of the Institutional Review Board.
Note: General footage of Dr. Feldman's lab and the Taubman Biomedical Science Research Building follow. News outlets may request broadcast-quality footage via [email protected].

Transcript:
Eva L. Feldman, M.D., Ph.D., Director of the A. Alfred Taubman Medical Research Institute at the University of Michigan: "We completed a Phase 1 FDA-approved trial where we injected stem cells into the spinal cord of patients with Lou Gehrig's disease (also known as ALS). We were able to show that it was a safe approach. The FDA has just approved for us to move forward and do what is called a "Phase 2 trial." In this trial we will be injecting stem cells into the upper part of the spinal cord of patients with Lou Gehrig's disease. Our goal is to continue to show that this approach is safe, and we will begin to look at whether this approach offers some benefit to our patients. We are also very pleased that we are going to be able to do these surgeries at the University of Michigan."

FDA approves Phase II clinical trial of stem cells for Lou Gehrig's disease (ALS)

More from this channel